Raul R. Rodriguez - 26 Jan 2026 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
CEO, President, Director
Signature
/s/ Raymond Furey (Attorney-in-Fact)
Issuer symbol
RIGL
Transactions as of
26 Jan 2026
Net transactions value
-$929,596
Form type
4
Filing time
04 Feb 2026, 16:20:33 UTC
Previous filing
17 Sep 2025
Next filing
12 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
RODRIGUEZ RAUL R CEO, President, Director RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO /s/ Raymond Furey (Attorney-in-Fact) 04 Feb 2026 0001190279

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RIGL Common Stock Options Exercise $1,096,000 +40,000 +17% $27.40 280,454 26 Jan 2026 Direct F1, F2
transaction RIGL Common Stock Tax liability $1,302,807 -35,211 -13% $37.00 245,243 26 Jan 2026 Direct
transaction RIGL Common Stock Options Exercise $1,096,000 +40,000 +16% $27.40 285,243 26 Jan 2026 Direct F1
transaction RIGL Common Stock Tax liability $1,310,688 -35,424 -12% $37.00 249,819 26 Jan 2026 Direct
transaction RIGL Common Stock Tax liability $508,101 -14,110 -5.6% $36.01 235,709 02 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Employee Stock Option (right to buy) Options Exercise $0 -40,000 -100% $0.000000 0 26 Jan 2026 Common Stock 40,000 $27.40 Direct F1, F3
transaction RIGL Employee Stock Option (right to buy) Options Exercise $0 -40,000 -100% $0.000000 0 26 Jan 2026 Common Stock 40,000 $27.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These numbers have been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.
F2 Includes 1,000 shares acquired under the Issuer's stock purchase plan.
F3 The shares vested monthly over two (2) years from January 1, 2016.